Compare Neurocrine Biosciences Inc (NBIX) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Starbucks Corp — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Starbucks Corp trades at $104.04 (market cap $119.45B). The key difference: Starbucks Corp is far larger — about 6.9× Neurocrine Biosciences Inc's market cap, and Starbucks Corp pays a 2.37% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SBUX | |
|---|---|---|
Market Cap | $17.40B | $119.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $108.37 |
52-Week Low | $123.10 | $78.46 |
Enterprise Value | $16.49B | $142.14B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.37% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
